dual BCMA-CD19 CAR-T / Xuzhou Medical University, Affiliated Hospital of Xuzhou Medical University - LARVOL DELTA

BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy (Eurekalert) - "The team reported for the first time using BCMA-CD19 bispecific CAR T cells for treating relapsed/refractory CIDP....After the initial 180-day follow-up, we checked in with them every 90 days to monitor any potential relapse. Remarkably, for more than a year, this patient could discontinue all immunosuppressants without disease recurrence, and the presence of GM4 and GD3 antibodies continued to diminish even after 3 months of CAR-T cell therapy....This case shows how viable, well-tolerated, and effective BCMA-CD19 bispecific CAR T cells are for treating stubborn/repetitive CIDP."

Clinical • Immunology